Table 4. Changes in Lipid Profile After 16 Weeks of Therapy
VariableTocilizumabAnti–TNF‐αsDMARD
BaselinePost‐TreatmentP ValueBaselinePost‐TreatmentP ValueBaselinePost‐TreatmentP Value
TC, mg/dL197.5 [177.59–217.36]232.3 [201.62–263.09]0.003a185.1 [158.16–212.06]192.9 [164.97–220.81]0.36185.8 [169.76–201.81]202.8 [176.81–228.76]0.04a
HDL‐C, mg/dL62.3 [52.47–72.12]63.8 [52.96–74.69]0.6358.8 [45.26–72.29]60.4 [44.75–76.14]0.5852.1 [45.33–58.96]55.5 [47.62–63.38]0.15
LDL‐C, mg/dL116.6 [101.03–132.19]137.0 [113.57–160.41]0.03a108.6 [88.67–128.44]115.1 [90.87–139.35]0.50111.5 [99.04–123.94]121.4 [101.66–141.11]0.09
Triglycerides, mg/dL92.6 [77.33–107.96]157.7 [116.55–198.86]<0.001a88.9 [67.88–109.90]86.7 [59.39–113.943]0.85110.8 [83.41–138.16]129.5 [85.45–173.55]0.19
TC/HDL‐C ratio3.36 [2.91–3.80]3.84 [3.25–4.43]0.02a3.35 [2.64–4.06]3.51 [2.64–4.38]0.513.75 [3.05–4.45]3.86 [3.08–4.64]0.44
  • Values are expressed as mean [95% CIs]. Anti–TNF‐α indicates anti–tumor necrosis factor α; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; sDMARD, synthetic disease‐modifying antirheumatic drug; TC, total cholesterol.

  • a Statistically significant.